Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,201–1,300 of 1,871
KAHL, S. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01369-z
Chronic Kidney Disease in Cardiovascular Pathologies
Obrișcă, B., & Ismail, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_4
Kent, P. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch14
Influence of Enrichment Criteria on eGFR Slope: Implications for Clinical Trial Design in CKD
Causland, F. R. M., Claggett, B. L., Chertow, G. M., & Heerspink, H. J. L. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107080
Hypertension in Diabetes: Numbers or Outcomes?
Koufakis, T., & Doumas, M. N. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00785-2
Emerging Cardiorenal Protective Therapies in Lupus Nephritis
Capón, I. M., Sandino, J., Galindo, M., & Morales, E. (2026) · Drugs · doi:10.1007/s40265-026-02337-7 · Cited by 2
“New therapies with antiproteinuric effects, such as GLP-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs), show promise for optimizing cardiovascular outcomes in LN with glomerular involvement, but robust LN-specific data remain limited [19, 20].”
Vijayan, A., Lanzinger, S., Forestier, N., Hess, G., Rottmann, M., Wosch, F. J., Seufert, J., Holl, R. W., Bramlage, P., & for the, D. P. V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16245
“15 Furthermore, basal insulin is frequently used in patients with T2D at later stages of renal disease.”
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Marqués-Vidas, M., Quiroga, B., Portolés, J. M., Ortíz, A., Fernández‐Fernández, B., Horrillo, A. S., Soler, M. J., García-Carro, C., Morales, E., & Bajo, M. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187201
“…T2D and https://doi.org/10.3390/jcm15187201 CKD, semaglutide reduced major kidney disease events by 24% (HR 0.76; 95% CI 0.66–0.88) and also reduced cardiovascular events and all-cause mortality [84], with consistent benefits across CKD stages and regardless of concomitant SGLT2i or MRA use [85].”
InfluentialHughes, M. S., & Pasquel, F. J. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.015
Hsu, H.-C., Shih, L., Hou, Y., & Lu, K. (2026) · Biomolecules · doi:10.3390/biom16081155
“GLP-1 receptor agonists [25] and metabolic-bariatric surgery [128] provide additional options in selected patients.”
InfluentialKról, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208
Zhong, Y., Tan, X., Zhang, L., & Wu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1916932 · Cited by 1
“The study by Perkovic et al. (2024) was flagged for “some concerns” in the domain of selective reporting of results.”
InfluentialShi, Y.-H., Zhang, T.-J., He, F., & Guo-Bin, K. (2026) · World Journal of Diabetes · doi:10.4239/wjd.117740
Clarifying the interpretation of semaglutide’s impact in the FLOW study
Ingwiller, M. (2025) · Kidney International · doi:10.1016/j.kint.2025.01.028
Blutdruckzielwerte und pharmakologische Blutdruckkontrolle bei chronischer Nierenkrankheit
van der Giet, M. (2025) · Nephrologie aktuell · doi:10.1055/a-2624-1048
74/m mit einer Überweisung: „Niereninsuffizienz“
Fleig, S. V. (2024) · Die Nephrologie · doi:10.1007/s11560-024-00773-8
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Fasieh, H., Naeem, A. B., & Hussain, M. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04185-4
Baumgarten, M., Gehr, T. W. B., Kothari, N. R., & Street, S. (2026) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_104-3
Cuenca, A. M. C., Martin, J. C., Guisasola, F. Á., Orozco‐Beltrán, D., Quesada, J., Menéndez, S. A., Cases, M. M., Ruiz-Quintero, M. A., & Pérez, A. P. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.02.007 · Cited by 2
Sargis, R. M., Reutrakul, S., Trasande, L., & Nadal, Á. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01635-4
“…our anti-diabetes armamentarium now includes agents that not only decrease blood sugars, but that also reduce microvascular complications [ 94 – 97 ], address common comorbidities and predisposing factors (e.g., obesity, MASLD, obstructive sleep apnea, hypertension) [ 98 –103], reduce…”
Yoshiji, S., & Inagaki, N. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70166
Zapp, C., Downer, D. M., Levine, A., Parker, N., Zapp, M., Downer, D. M., & Levine, L. (2026) · Cureus · doi:10.7759/cureus.102921 · Cited by 2
“There is also reduced cardiovascular death, heart attack, stroke, chronic kidney disease in diabetics, and cravings in substance abuse disorders [16-18].”
Li, H., Peng, S., & Lei, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1957367
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Fritsche, A., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., et al. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01324-y
“Auch für den GLP-1RA Semaglutid zeigten sich in der FLOW-Studie vorteilhafte Effekte [82].”
Chen, W., Hou, S., & Hu, J. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04701-3
“DKD, a primary driver of ESKD, has a range of effective therapies, from traditional RAS blockers to modern SGLT2 inhibitors, NS-MRAs, and GLP-1 receptor agonists [1, 64].”
Immunosenescence in Cardiovascular-Kidney-Metabolic Syndrome: A Unifying Mechanistic Framework
Sano, M. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0060
Gerdes, C., & Wolf, G. (2026) · Diabetes aktuell · doi:10.1055/a-2759-5230
“%) im Ver gleich zu einer Monotherapie mit Dapagliflozin (19,6 % 95%-KI 34,3–1,5”
CİNDOĞLU, Ç., Karaaslan, H., Uyar, N., GÖKÇE, A., GÖKÇE, B. D., & Eren, M. A. (2026) · ASIDE Internal Medicine · doi:10.71079/aside.im.040826358
“…the current literature that GLP-1RAs have a significant adverse effect on liver function tests and renal parameters; on the contrary, there are findings that they may improve kidney-related outcomes and liver-related biomarkers in patients with chronic kidney disease or fatty liver disease [19–21].”
Executive Summary of the ASN Kidney Health Guidance on the Cardiovascular‑Kidney‑Metabolic Syndrome
Navaneethan, S. D., Rifkin, B. S., Mottl, A. K., & Syndrome, O. B. O. T. A. K. H. G. W. O. T. C.-K.-M. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001230
Effetti renali dei farmaci basati sul sistema delle incretine nelle persone con diabete di tipo 2
Caruso, I., Amato, C., Gravina, F., Montingelli, A., Giorgino, F., & Laviola, L. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01625-w
Chilunga, F. P., & Mkoma, G. F. (2024) · Diabetologia · doi:10.1007/s00125-024-06297-z · Cited by 1
A systematic review of semaglutide-associated kidney injury case reports
Xiu, X., Zheng, P., Li, Y., Du, M., Min, X., Pang, X., Zhang, L., Liu, J., Zhao, Z., Liu, Z.-C., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1793349
Current Options for Kidney Protection: Are Renin–Angiotensin System Inhibitors Still Relevant?
Wong, W. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151689
Turchin, A., Petito, L. C., Hegermiller, E., Chelliah, I., Carnahan, R. M., DEVRIES, A. R., Goel, S., Lansang, M. C., McDonnell, M. E., Nair, V. P., et al. (2026) · BMJ · doi:10.1136/bmj-2026-100574
“11 24 25 11-13 Our findings suggest that the renal benefits shown in these studies for new type 2 diabetes drugs—GLP-1 receptor agonists and SGLT-2 inhibitors—do not extend to people without albuminuria.”
Narula, J., Butler, J., Chothia, M., Banerjee, D., Jarraya, F., Ulasi, I., & Luyckx, V. A. (2025) · Indian Journal of Nephrology · doi:10.25259/ijn_215_2025
Ma, Y., Chen, S., Shen, Y., Wang, X., Xie, X., & Zhao, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1582534 · Cited by 1
ภาวะอ้วนและโรคไต: กลไกและการรักษาใหม่
ศุภศิลป์, ฐ., & สถิระพจน์, บ. (2026) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2026.289162
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Risk Factors and Outcome in Living Kidney Donors: A Narrative Review
Discălicău, L.-G., Baston, C., Sorohan, B. M., Moldoveanu, O., Margaritis, S., Vișinescu, P.-M., & Sinescu, I. C. (2026) · Kidney and Dialysis · doi:10.3390/kidneydial6020028
“Although these therapies have not been specifically studied in living kidney donors, they may represent promising tools for metabolic optimization before and after donation [10,11,31,32].”
GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension
Al‐Ali, D., & Hajj, N. E. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113325
Ma, C., Wu, L., Li, Y., Yang, B., Tan, J., Liu, S., Siddiqui, F. J., Gandhi, M., & Jafar, T. H. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000996 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Self-citationNasir, L., Jalal, L., Siddiqa, A., Nasir, A., Farooqui, M., & Siddiqui, A. H. (2025) · European Journal of Therapeutics · doi:10.58600/eurjther2817
Huang, C., Lai, E. C., Wu, V., Hsieh, M. H., Li, C.-J., Chang, R., Chen, J.-S., Tsai, Y.-S., & Sung, J. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag028
Sanyal, A. J., Parmar, K., de Oliveira, A. B. S., Jahagirdar, V., & Smirnova, E. (2026) · Research Square · doi:10.21203/rs.3.rs-8342646/v1
Obesity in Living Kidney Donors from Risk to Ethics: Bridging Gaps in Evaluation and Management
Budhiraja, P., Bzoma, B., Đenić, A., Issa, N. S., McKee, K., Schinstock, C., Taler, S. J., Chakkera, H. A., Heimbach, J. K., Jadlowiec, C. C., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001030 · Cited by 2
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
GLP-1 receptor agonists: from glycaemic control to cardio-reno-metabolic disease modification
Farmakis, D. T., Karampinos, K. I., & Filippatos, G. S. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag096
DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic Fabry disease
Riccio, E., Cuomo, A., Capuano, I., Spinelli, L., Iaccarino, G., Marco, O. D., & Pisani, A. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag115
Noninsulin Medications for Type 2 Diabetes
CASTRO-REVOREDO, I. A., & WEBSTER, S. C. M. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.12.006
Pursuing a World without Kidney Diseases: A Hero's Journey
Josephson, M. A. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000549
Kodama, G., Taguchi, K., Wada, Y., Nakano, K., Shibata, R., & Fukami, K. (2026) · Toxins · doi:10.3390/toxins18010029 · Cited by 1
“…glycemic control with glucose-lowering agents such as metformin [11], controlling blood pressure with renin–angiotensin system (RAS) blockade [12], and using sodium–glucose cotransporter 2 (SGLT2) inhibitors [13] and GLP-1 receptor agonists [14] have been shown to slow disease progression.”
Nephrology 2050: an evidence-informed roadmap from precision prevention to kidney regeneration
Soliman, A. R., Fayed, A., & Khashab, S. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05338-3
Brogaard, E., Nielsen, V. W., Pedersen, N. H., & Thomsen, S. F. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2738341
Blood Pressure, Kidney Function, and Kidney Mortality Among Mexican Adults
Zhu, D., Kuri-Morales, P., Wade, R. L., Staplin, N., Garcilazo‐Ávila, A., González-Carballo, C., Ramírez-Reyes, R., Aguilar-Ramirez, D. J., Baigent, C., Bragg, F., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.05.019
Stepwise management of chronic kidney disease in primary care
Varma, R., & Ravindran, N. (2026) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380261435934
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
Factors Contributing to Obesity Among Indigenous Peoples of Canada: A Narrative Review
Aminaei, D., Ahmed, M., Ozlati, A., Clemens, K. K., Jain, A., Reichert, S. M., Harris, S., Ernst, J., & MOIST, L. M. (2026) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581261472119
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
RAAS blockade in the kidney life-cycle–treatment standard
Moriconi, D., García-Carro, C., Núñez, J. E., Correa‐Rotter, R., Tuttle, K., & Soler, M. J. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag090 · Cited by 1
Self-citationMicrovascular complications of diabetes - their prevention and treatment
Lášticová, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.079
Yi, Y., Park, S., Jeong, J. C., Na, K. Y., Chin, H. J., Yoo, S., Kim, S., Jung, C. H., Oh, J. S., Baek, G., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10180696/v1
Tentolouris, A., Popovic, D. S., Liarakos, A. L., Briasoulis, Α., Παπάνας, Ν., & Koufakis, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71045
“In T2D, CV outcome trials have consistently demonstrated that GLP- 1-based therapies confer the greatest absolute risk reduction in individuals with established CV disease, elevated CV risk, or CKD, where baseline event rates are highest [10–17].”
InfluentialGLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient
Burboa, G. U. V., & Guillén, M. Á. R. F. (2026) · Skin Appendage Disorders · doi:10.1159/000552598
Girard, L. (2024) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2024.2333
Documento de posicionamiento de SEMERGEN sobre la enfermedad renal crónica
Pérez-León, N., García, J. P., Alonso-Álvarez, M. P., & Martínez-Berganza-Asensio, L. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102690 · Cited by 1
Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
Zeitler, E. M., Klein, K. R., Lingvay, I., Pick, A., & Billings, L. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70781 · Cited by 2
“Large-scale randomized controlled trials involving semaglutide have also demonstrated the beneficial cardiovascular and kidney effects of pharmacologic weight loss [12, 69] but how much of this is mediated by improvements in aldosterone signalling via semaglutide action is not known.”
Refaeli, R., Green, G., Boaz, M., Dotan, I., Raziel, A., Peffer-Gik, T., Buch, A., & Dagan, S. S. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01887-2 · Cited by 2
CARDIOVASCULAR AND METABOLIC INTERRELATIONS IN CHRONIC KIDNEYDISEASE
Rashidov, I., & OLIMOV, O. Z. (2025) · SCIENCE AND EDUCATION · doi:10.25005/3078-5022-2025-2-2-235-243
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Badgandi, M., Srinath, A., Mandora, V., Kandar, D. K., Shukla, P., PUNATAR, D. H., Jain, V., Kumar, S., Girish, P., Budhwar, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_20_26
A clinical and experimental investigation of liraglutide effects on the brain-kidney axis
Greenwood, M. P., Alotaibi, M. I., Bárez‐López, S., Cantley, N. W. P., Merritt, S., Tatović, D., & Murphy, D. (2026) · Science Advances · doi:10.1126/sciadv.aef4951
Салухов, В. В., Galstyan, G. R., Неймарк, А. Е., Samoilov, V. S., Khalimov, Y. S., Karonova, T. L., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-155
Perkovic, V., Tuttle, K. R., Rossing, P. R., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.008
Self-citationC-peptide and epicardial adipose tissue in dialysis-dependent chronic kidney disease patients
D’Marco, L., Checa-Ros, A., Locascio, A., Okojie, O. J., Viejo-Boyano, I., Bermúdez, V., Karohl, C., & Raggi, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1650859
“Not only do these drugs control glycemia in T2DM, but they also slow kidney dysfunction progression in patients with CKD not on dialysis (40–45), besides inducing significant weight loss without provoking episodes of hypoglycemia (46).”
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M. A., Siegel, E. G., et al. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01469-4
Übergewicht und Frauengesundheit: Gynäkologische Erkrankungen im Zusammenhang mit Adipositas
Franz, M. (2025) · gynäkologie + geburtshilfe · doi:10.1007/s15013-025-6117-9
“In verschiedenen Studien konnten verschiedene positive Wirkungen von Semaglutid und Tirzepatid gezeigt werden [14, 15, 16]: — Verbesserung/Entfettung der Leber bei nicht alkoholischer Fettleber In einer Studie, die vor Kurzem in „Nature Medicine“ publiziert wurde, analysierten Forschende anhand der…”
Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!
Lee-Barkey, Y. H., Arbi, A., Parizova, S., Danch, E., Willecke, F., Stratmann, B., & Tan, S. (2025) · Gefässchirurgie · doi:10.1007/s00772-025-01211-2
Glucagon-Like Peptide-1 Receptor Agonists
Whitley, H. P. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch13
Elsayed, A., Ayoub, W. J., ELSAYED, N., Stephens, J. P., Udongwo, N., Elsayed, Y. A.-E., & Ghali, J. K. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00322-3
Khan, I. I., & Lanktree, M. B. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.240469
Yoo, M. J., & Lee, S. (2026) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2026.24.e13
“Alongside their established cardiorenal benefits [40-42], GLP-1 RAs induce mild natriuresis similar to SGLT2 inhibitors [43].”
Yamanouchi, M., Sawa, N., Furuichi, K., & Wada, T. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101516
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Ciancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Prise en charge pharmacologique de l’obésité : l’apport des nouvelles classes médicamenteuses
Bauduceau, B., Bordier, L., Schlienger, J.-L., & Monnier, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.008 · Cited by 5
El‐Sheikh, M., Sillassen, C. D. B., Wisborg, F. D., Hove, J. D., Dirksen, C., Lee, M. M. Y., Jakobsen, J. C., & Grand, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103668 · Cited by 2
Pakulska, A. O., Rządzińska, N., Błoch, A. M., Fimiarz, K. J., Kłosowicz, A. K., Miller, M. A., & Kamińska, A. J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5685
Stages of Disease Progression in Cardiovascular-Kidney-Metabolic Syndrome
Godun, M. M., Floria, D., & Floria, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_10
Perkovic, V., Francis, S. L., Zhang, H., Gao, Y., Lv, J., Li, H., Yan, Y., 张郁苒, Liu, C., Zhang, H., et al. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107037
“8 As such, it may be that glomerular hyperfiltration and podocyte depletion are dual drivers of glomerular injury and DKD progression.”
Self-citationSemaglutide reduces proteomic organ-specific biological age across randomized clinical trialsPreprint
Dermit, M., Colhoun, H. M., Goeminne, L. J. E., Ryan, D. H., Adelborg, K., Belmont-Rausch, D. M., Kolnes, K. J., Knop, F. K., Voisin, S. A. C., Gladyshev, V. N., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-11082091/v1
Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead
Wang, S. S. Y., Chan, Y. Z., Luo, X. R., Tan, N. A. M. R., Klein, M., & Javaid, M. M. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-240
Yuan, Y., Chen, C., Li, X., Guo, J., Liu, Q., Lin, Y., Sun, L., & Fan, G. (2026) · Drugs · doi:10.1007/s40265-026-02380-4
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
Khan, S. S., Ndumele, C. E., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.007 · Cited by 4
Reges, O., Ahmad, W. A., Ramot, N., Battat, E., Greenland, P., Arbel, R., Sagy, Y. W., Lavie, G., & Diker, D. (2026) · Obesity Facts · doi:10.1159/000551805
“The strong beneficial effect of GLP-1R in people living with diabetes was also demonstrated in the Flow trial [18] that was terminated earlier than planned due to the significant beneficial effect of semaglutide 1 mg on deterioration of chronic kidney disease, major cardiac events, and other causes…”
Mitigating heart failure risk in patients with diabetes and chronic kidney disease
Kowalczyk, N. S., & Prochaska, M. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001208
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.